Managing Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT): A Comprehensive Narrative Review of Therapeutic Horizons

Youssef El Sayed Ahmad,Smile Kajal,Akaber Halawi

DOI: https://doi.org/10.1017/s0022215124002093

2024-11-13

The Journal of Laryngology & Otology

Abstract://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS0022215124002093/resource/name/firstPage-pdf-S0022215124002093a.jpg

otorhinolaryngology

What problem does this paper attempt to address?

Surgical Extraction in a Patient with Hereditary Hemorrhagic Telangiectasia - A Case Report

Yan-Rung Chen,Chi-Kung Lin,Yi‐Shing Shieh,Yibing Wang,Yuan-Wu Chen

DOI: https://doi.org/10.6566/jfd/2016.11(1).18

2016-01-01

Abstract:Hereditary hemorrhagic telangiectasia (HHT) is a rare inherited, autosomal dominant, mucocutaneous disease. The reported prevalence is approximately 1 in 5,000-10,000 per year. Its clinical characteristics are recurrent epistaxis, vascular hamartomas on the skin and oral mucosa, and arteriovenous malformations of soft tissues. Dentists play a vital role in diagnosing HHT because they are the first one to identify its signs. HHT is clinically diagnosed on the basis of the Curacao criteria; in other words, a diagnosis is made when three of the following four criteria are met: epistaxis, telangiectasias, visceral arteriovenous malformation, or a family history of the disease. Here, we report our dental therapeutic experience of managing a patient with HHT.
How I Treat Bleeding in Hereditary Hemorrhagic Telangiectasia

Hanny Al-Samkari

DOI: https://doi.org/10.1182/blood.2023021765

IF: 20.3

2024-06-14

Blood

Abstract:Hereditary hemorrhagic telangiectasia (HHT, Osler-Weber-Rendu disease) affects 1 in 5,000 persons, making it the second most common inherited bleeding disorder worldwide. Telangiectatic bleeding, primarily causing recurrent epistaxis and chronic gastrointestinal bleeding, is the most common and most important manifestation of this multisystem vascular disorder. HHT-associated bleeding results in substantial psychosocial morbidity and iron deficiency anemia that may be severe. Although there remain no regulatory agency-approved therapies for HHT, multiple large studies, including randomized controlled trials, have demonstrated the safety and efficacy of antifibrinolytics for mild-to-moderate bleeding manifestations and systemic antiangiogenic drugs including pomalidomide and bevacizumab for moderate-to-severe bleeding. This has led to a recent paradigm shift away from repetitive temporizing procedural management towards effective systemic medical therapeutics to treat bleeding in HHT. In this article, 4 patient cases are used to illustrate the most common and most challenging presentations of HHT-associated bleeding that hematologists are likely to encounter in daily practice. Built on a framework of published data and supported by extensive clinical experience, guidance is given for modern evidence-based approaches to antifibrinolytic therapy, antiangiogenic therapy, and iron deficiency anemia management across the HHT disease severity spectrum.

hematology
Surgery or No Surgery? Exploring the Dilemma of Epistaxis Management in Patients with HHT

Giulio Cesare Passali,Mariaconsiglia Santantonio,Nadia Vecchioli,Michela Sollazzo,Rolando Rolesi,Ilenia Marotta,Luigi Corina,Maria Elena Riccioni,Eleonora Gaetani,Jacopo Galli

DOI: https://doi.org/10.3390/jcm13061688

IF: 3.9

2024-03-15

Journal of Clinical Medicine

Abstract:Background: Epistaxis, particularly in Hereditary Hemorrhagic Telangiectasia (HHT) patients, is a common otolaryngological emergency, often requiring complex management. A hierarchy of increasingly invasive interventions, from external compression of the nasal pyramid to nostril closure, is typically proposed and applied. Methods: We conducted a retrospective study on HHT patients to assess the effectiveness and longevity of invasive procedures postoperatively. Data were collected using the Epistaxis Severity Score (ESS) questionnaire. The primary focus was on changes in the frequency and intensity of epistaxis, while the secondary focus was on the overall quality of life. Results: This study found that invasive procedures initially improved the frequency and intensity of epistaxis in HHT patients. However, within 1 to 9 months postoperatively, these benefits often diminished, with hemorrhagic symptoms recurring at similar or worsened levels. Conclusions: The findings suggest a need for a cautious and restrained approach to using invasive treatments in managing epistaxis in HHT patients. Highly invasive procedures should be reserved for cases where less invasive methods fail, due to their temporary effectiveness and the risk of causing anatomical–functional changes in the rhino-sinus area, complicating future management of severe epistaxis.

medicine, general & internal
Is there still a role for nasal closure in hereditary haemorrhagic telangiectasia?

Robert Bickerton,Benjamin Kennard,Nikita Mehtani,Elizabeth Bullock,Talisa Ross,Vikas Acharya,Catherine Rennie

DOI: https://doi.org/10.1017/s0022215124001300

2024-10-22

The Journal of Laryngology & Otology

Abstract://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS0022215124001300/resource/name/firstPage-pdf-S0022215124001300a.jpg

otorhinolaryngology
Medical and Interventional Management of Hereditary Hemorrhagic Telangiectasia

Jeffrey M. Lynch,Elizabeth Stevens,Mary E. Meek

DOI: https://doi.org/10.1055/s-0044-1791186

2024-11-09

Seminars in Interventional Radiology

Abstract:Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder of the blood vessels that leads to the formation of telangiectasias and arteriovenous malformations (AVMs). HHT affects ∼1/5,000 people, but this varies significantly by geography and ancestry. The Curaçao criteria for HHT consist of four diagnostic criteria: spontaneous epistaxis, first-degree relative with HHT, AVMs in characteristic location (liver, lung, brain), and telangiectasias. Sequelae and major symptomology include recurrent epistaxis, dyspnea, heart failure, and stroke from paradoxical emboli among others. HHT patients are best cared for by a multidisciplinary team, ideally all with HHT-specific experience, but in this review, we will discuss the major aspects of the disease including etiology, diagnosis, and treatment recommendations. Article published online: 07 November 2024 © 2024. Thieme. All rights reserved. Thieme Medical Publishers, Inc. 333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

radiology, nuclear medicine & medical imaging
Hereditary hemorrhagic telangiectasia – pediatric review

Ionela Iacobas,Adrienne M. Hammill

DOI: https://doi.org/10.1097/mop.0000000000001398

2024-09-10

Current Opinion in Pediatrics

Abstract:Purpose of review Hereditary hemorrhagic telangiectasia (HHT) diagnostic and management approach for pediatrics underwent significant advances over the last couple of years. Recent findings In 2020, new guidelines for HHT were published that included a pediatric section thus attracting special focus into the childhood presentation. Summary Curacao criteria are specific, but not sensitive enough in children. Genetic testing is encouraged for all family members even if asymptomatic. Standardized scoring for epistaxis is strongly encouraged, as it allows monitoring and can stratify therapeutic approaches. Early screening for pulmonary and brain visceral arteriovenous malformations (AVMs) in pediatric patients with confirmed genetic alterations of HHT should be instituted. Graded trans-esophageal echocardiogram with agitated saline contrast can be used as screening method for pulmonary AVMs. As pulmonary AVMs can develop throughout lifetime, guidelines recommend repeated screening even in asymptomatic patients at least every 5 years. Signs of stroke in childhood are more subtle than in adults. Cerebral imaging in early childhood can identify brain AVMs that may benefit from early intervention. Embolization of high-risk pulmonary and cerebral AVMs should be performed at specialized centers even at pediatric age. One or two classic HHT telangiectasia can be considered diagnostic in children. Antibiotic prophylaxis with dental procedures continues to be recommended.

pediatrics
Hereditary Hemorrhagic Telangiectasia: A Pediatric-Focused Review

Chelsey Ortman,Elissa Ortolani

DOI: https://doi.org/10.1016/j.spen.2024.101167

IF: 3.042

2024-11-04

Seminars in Pediatric Neurology

Abstract:Clinical manifestations of hereditary hemorrhagic telangiectasia (HHT) include vascular malformations of the skin, nasal mucosa, gastrointestinal tract, lungs, liver and central nervous system. These malformations range from punctate telangiectasias to larger arteriovenous malformations within visceral organs and the central nervous system. Vascular malformations increase risk for acute and chronic bleeding, anemia, as well secondary complications related to arterial-venous shunting. Diagnosis can be made with the Curaçao criteria, which includes the presence of epistaxis, telangiectasias, arteriovenous malformations, and first-degree family member with HHT. Nearly all patients with HHT will have a pathogenic variant in the ENG or ACVRL1 genes, while a smaller number will have a variant in SMAD4 or no clear genetic etiology. While there is no cure for HHT, medical management of vascular complications may include oral tranexamic acid and IV bevacizumab. Endovascular and surgical treatments are clinically indicated when the benefits outweigh the risks of the interventions.

pediatrics,clinical neurology
Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances

Tala Al Tabosh,Mohammad Al Tarrass,Laura Tourvieilhe,Alexandre Guilhem,Sophie Dupuis-Girod,Sabine Bailly

DOI: https://doi.org/10.1172/jci176379

IF: 19.456

2024-02-16

Journal of Clinical Investigation

Abstract:Hereditary hemorrhagic telangiectsia (HHT) is an inherited vascular disorder with highly variable expressivity, affecting up to 1 in 5,000 individuals. This disease is characterized by small arteriovenous malformations (AVMs) in mucocutaneous areas (telangiectases) and larger visceral AVMs in the lungs, liver, and brain. HHT is caused by loss-of-function mutations in the BMP9-10/ENG/ALK1/SMAD4 signaling pathway. This Review presents up-to-date insights on this mutated signaling pathway and its crosstalk with proangiogenic pathways, in particular the VEGF pathway, that has allowed the repurposing of new drugs for HHT treatment. However, despite the substantial benefits of these new treatments in terms of alleviating symptom severity, this not-so-uncommon bleeding disorder still currently lacks any FDA- or European Medicines Agency–approved (EMA-approved) therapies.

medicine, research & experimental
Hereditary haemorrhagic telangiectasia: A primer for the paediatrician

Yoshua Selvadurai,Emily R Le Fevre,Jonathan Mervis,Dominic A Fitzgerald

DOI: https://doi.org/10.1016/j.prrv.2024.07.003

2024-08-02

Abstract:Hereditary haemorrhagic telangiectasia (HHT) is an autosomal dominant condition characterised by small telangiectasias and larger multisystem arteriovenous malformations (AVMs). Common sites of AVMs include in the nose, lungs, brain and liver. These lesions are prone to rupture, leading to complications including recurrent epistaxis and significant haemorrhage. Pulmonary hypertension (PH) can also occur. This review presents an update on the genetics, clinical manifestations, management options, and screening recommendations for children with HHT.
Pulmonary hypertension in hereditary hemorrhagic telangiectasia: A clinical review

Akash Mathavan,Akshay Mathavan,Renuka Reddy,Kirk Jones,Christina Eagan,Hassan Alnuaimat,Ali Ataya

DOI: https://doi.org/10.1002/pul2.12301

2023-10-21

Pulmonary Circulation

Abstract:Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant hereditary disorder characterized by recurrent spontaneous epistaxis, mucocutaneous telangiectasias, and solid organ arteriovenous malformations (AVMs). Pulmonary hypertension (PH) is an increasingly recognized complication in patients with HHT, most often precipitated by high‐output heart failure in the presence of hepatic AVMs as well as pulmonary arterial hypertension in the form of a proliferative vasculopathy. The presence of PH in patients with HHT is associated with significant elevations in rates of morbidity and mortality. Additionally, there is growing recognition of a thromboembolic propensity in this population that increases the risk of chronic thromboembolic PH, posing unique clinical considerations regarding the use of anticoagulation. Patients with HHT are also at risk of PH due to disorders commonly seen in the general population, including left‐sided heart and lung disease. The etiology of PH in HHT is multifaceted and complex; the diagnostic approach and treatment strategies must consider the underlying pathophysiology of HHT. This comprehensive review summarizes current knowledge of PH in HHT, detailing the pathogenesis of known etiologies, diagnostic evaluation, and suggested treatment modalities as well as emerging therapies that may be of future interest.

cardiac & cardiovascular systems,respiratory system
Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia

Arno Amann,Normann Steiner,Eberhard Gunsilius

DOI: https://doi.org/10.1007/s00508-015-0789-4

Abstract:Background: Recurrent epistaxis in hereditary haemorrhagic telangiectasia (HHT) patients significantly decreases their quality of life. Treatment in therapy refractory patients is limited although various options have been tested so far. Case report: Herein, one patient is described that was treated for HHT for over 20 years with only intermediate benefits. As epistaxis duration and frequency increased continuously, bevacizumab 5 mg/kg was administered every 2 weeks. During the time of treatment (six doses) and up to 3 month afterwards clinical symptoms, blood pressure, cardiac output, pulmonary arterial hypertension (PAH), bleeding duration and frequency were assessed as criteria for treatment benefit. Results: Duration and frequency of epistaxis decreased immediately after the first application resulting in reduced need of blood transfusions. After completion of six cycles, a further decrease in frequency and duration of bleeding was noted. Cardiac output and PAH decreased or remained stable, respectively, during time and after treatment. No increase in blood pressure could be found but a significant increase in heart rate was experienced after completion of all six applications. Unfortunately, the patient died due to a cerebral abscess. Conclusion: Bevacizumab led to an improvement of HHT related epistaxis, refractory to other treatments.
S3661 The Perpetual Hemorrhage: Managing Recurrent Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia

Kimberly Tena Diaz,Kathy N. Williams,Apeksha Shah,Adib Chaaya,Tonia Liu

DOI: https://doi.org/10.14309/01.ajg.0001044012.16406.f3

2024-10-26

The American Journal of Gastroenterology

Abstract:Hereditary hemorrhagic Telangiectasia (HHT) is a genetic disorder that leads to arteriovenous malformations (AVMs) partly due to the lack of capillaries. HHT has an age-related penetrance with progressive AVM formations that may form anywhere, but most often form in the nasal, pulmonary, hepatic or cerebral circulation. Despite this, 15-20% of patients with HHT experience recurrent gastrointestinal (GI) bleeding. Our aim is to bring awareness to treatment options in a patient with HHT and recurrent GI AVM bleeding.

gastroenterology & hepatology
Classification of endonasal HHT lesions using digital microscopy

F. Haubner,A. Schneider,H. Schinke,M. Bertlich,B. G. Weiss,M. Canis,F. Kashani

DOI: https://doi.org/10.1186/s13023-021-01801-9

2021-04-17

Orphanet Journal of Rare Diseases

Abstract:Abstract Background Recurrent spontaneous epistaxis is the most common clinical manifestation and the most debilitating symptom in hereditary haemorrhagic telangiectasia (HHT) patients. To this date, there exist only a classification of HHT patients by different genetic mutations. There is no standard classification for the mucocutaneous endonasal manifestations of HHT. The aim of the present study was to document the variety of endonasal HHT lesions using digital microscopy and to propose a clinical classification. Methods We recorded the endonasal HHT lesions of 28 patients using a digital microscope. We reconstructed the 3D images und videos recorded by digital microscope afterwards and classified the endonasal lesions of HHT in two classes: Grade A, presence of only flat telangiectasias in the mucosa level and Grade B, (additional) presence of raised berry or wart-like telangiectasia spots. We investigated also Haemoglobin level by routine laboratory procedures, plasma VEGF level by ELISA, Severity of epistaxis by epistaxis severity score (ESS) and quality of life by a linear visual analogue scale (VAS). Results We found a higher quality of life and a lower severity of epistaxis in Grade A patients in comparison to Grade B patients. No difference in plasma VEGF level and in Haemoglobin between Grad A patients and Grade B patients could be detected. Plasma VEGF levels showed no gender specific differences. It could also not be correlated to the extranasal manifestation. Conclusion The classification for endonasal manifestation of HHT proposed in this study indicates severity of epistaxis und quality of life. Digital microscopy with the ability of 3D reconstruction of images presents a useful tool for such classifications. The classification of endonasal HHT lesions using digital microscopy allows to evaluate the dynamic of HHT lesions in the course of time independent of examiner. This allows also to evaluate the efficacy of the different treatment modalities by dynamic of HHT lesions. Moreover digital microscopy is very beneficial in academic teaching of rare diseases.

genetics & heredity,medicine, research & experimental
Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia

Marie E Faughnan,Johannes J Mager,Steven W Hetts,Valerie A Palda,Kelly Lang-Robertson,Elisabetta Buscarini,Erik Deslandres,Raj S Kasthuri,Andrea Lausman,David Poetker,Felix Ratjen,Mark S Chesnutt,Marianne Clancy,Kevin J Whitehead,Hanny Al-Samkari,Murali Chakinala,Miles Conrad,Daniel Cortes,Claudia Crocione,Jama Darling,Els de Gussem,Carol Derksen,Sophie Dupuis-Girod,Patrick Foy,Urban Geisthoff,James R Gossage,Adrienne Hammill,Ketil Heimdal,Katharine Henderson,Vivek N Iyer,Anette D Kjeldsen,Masaki Komiyama,Kevin Korenblatt,Jamie McDonald,Jack McMahon,Justin McWilliams,Mary E Meek,Meir Mei-Zahav,Scott Olitsky,Sara Palmer,Rose Pantalone,Jay F Piccirillo,Beth Plahn,Mary E M Porteous,Marco C Post,Ivan Radovanovic,Paul J Rochon,Josanna Rodriguez-Lopez,Carlo Sabba,Marcelo Serra,Claire Shovlin,Dennis Sprecher,Andrew J White,Ingrid Winship,Roberto Zarrabeitia

DOI: https://doi.org/10.7326/M20-1443

2020-12-15

Abstract:Description: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of vascular malformations (VMs). These result in chronic bleeding, acute hemorrhage, and complications from shunting through VMs. The goal of the Second International HHT Guidelines process was to develop evidence-based consensus guidelines for the management and prevention of HHT-related symptoms and complications. Methods: The guidelines were developed using the AGREE II (Appraisal of Guidelines for Research and Evaluation II) framework and GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology. The guidelines expert panel included expert physicians (clinical and genetic) in HHT from 15 countries, guidelines methodologists, health care workers, health care administrators, patient advocacy representatives, and persons with HHT. During the preconference process, the expert panel generated clinically relevant questions in 6 priority topic areas. A systematic literature search was done in June 2019, and articles meeting a priori criteria were included to generate evidence tables, which were used as the basis for recommendation development. The expert panel subsequently convened during a guidelines conference to conduct a structured consensus process, during which recommendations reaching at least 80% consensus were discussed and approved. Recommendations: The expert panel generated and approved 6 new recommendations for each of the following 6 priority topic areas: epistaxis, gastrointestinal bleeding, anemia and iron deficiency, liver VMs, pediatric care, and pregnancy and delivery (36 total). The recommendations highlight new evidence in existing topics from the first International HHT Guidelines and provide guidance in 3 new areas: anemia, pediatrics, and pregnancy and delivery. These recommendations should facilitate implementation of key components of HHT care into clinical practice.
Executive summary of the 14th HHT international scientific conference

Roxana Ola,Josefien Hessels,Adrienne Hammill,Cassi Friday,Marianne Clancy,Hanny Al-Samkari,Stryder Meadows,Vivek Iyer,Rosemary Akhurst

DOI: https://doi.org/10.1007/s10456-023-09886-5

IF: 10.658

Angiogenesis

Abstract:Hereditary Hemorrhagic Telangiectasia (HHT) is an autosomal dominant vascular disorder characterized by small, dilated clustered vessels (telangiectasias) and by larger visceral arteriovenous malformations (AVMs), which directly connect the feeding arteries with the draining veins. These lesions are fragile, prone to rupture, and lead to recurrent epistaxis and/or internal hemorrhage among other complications. Germline heterozygous loss-of-function (LOF) mutations in Bone Morphogenic Protein 9 (BMP9) and BMP10 signaling pathway genes (endoglin-ENG, activin like kinase 1 ACVRL1 aka ALK1, and SMAD4) cause different subtypes of HHT (HHT1, HHT2 and HHT-juvenile polyposis (JP)) and have a worldwide combined incidence of about 1:5000. Expert clinicians and international scientists gathered in Cascais, Portugal from September 29th to October 2nd, 2022 to present the latest scientific research in the HHT field and novel treatment strategies for people living with HHT. During the largest HHT scientific conference yet, participants included 293 in person and 46 virtually. An impressive 209 abstracts were accepted to the meeting and 59 were selected for oral presentations. The remaining 150 abstracts were presented during judged poster sessions. This review article summarizes the basic and clinical abstracts selected as oral presentations with their new observations and discoveries as well as surrounding discussion and debate. Two discussion-based workshops were also held during the conference, each focusing on mechanisms and clinical perspectives in either AVM formation and progression or current and future therapies for HHT. Our hope is that this paper will represent the current progress and the remaining unanswered questions surrounding HHT, in order to serve as an update for those within the field and an invitation to those scientists and clinicians as yet outside of the field of HHT.
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia

Hanny Al-Samkari,Raj S. Kasthuri,Vivek N. Iyer,Allyson M. Pishko,Jake E. Decker,Clifford R. Weiss,Kevin J. Whitehead,Miles B. Conrad,Marc S. Zumberg,Jenny Y. Zhou,Joseph Parambil,Derek Marsh,Marianne Clancy,Lauren Bradley,Lisa Wisniewski,Benjamin A. Carper,Sonia M. Thomas,Keith R. McCrae

DOI: https://doi.org/10.1056/nejmoa2312749

IF: 158.5

2024-09-20

New England Journal of Medicine

Abstract:New England Journal of Medicine, Volume 391, Issue 11, Page 1015-1027, September 19, 2024.

medicine, general & internal
Usefulness of endoscopic endonasal underwater surgery using a combination of coblation and a lens-cleaning system for hemostasis in hereditary hemorrhagic telangiectasia

Hiroshi Sakaida,Masayoshi Kobayashi,Kazuhiko Takeuchi

DOI: https://doi.org/10.1016/j.anl.2024.02.007

IF: 2.119

2024-03-25

Auris Nasus Larynx

Abstract:Hemostatic procedures for controlling nasal bleeding in refractory diseases such as hereditary hemorrhagic telangiectasia (HHT) can be challenging. In this report, we present a novel technique for underwater endoscopic endonasal hemostatic surgery, which was performed on a 69-year-old man with HHT. The patient had been experiencing frequent episodes of nasal bleeding and had many telangiectasias in the nasal cavity, which were the cause of the bleeding. These telangiectasias were effectively treated using a coblation device in combination with an endoscope lens-cleaning system that supplied saline to create stable underwater conditions. There are several advantages to this technique, including provision of a stable and clear endoscopic field of view, allowing for better visualization of the surgical site. This makes it easier to identify bleeding points and ensure accurate hemostasis. Additionally, the hydrostatic pressure created by the underwater environment helps to reduce bleeding during the procedure. However, it is important to take careful precautions to prevent water from entering the lower airway. With this precautionary measure, this technique is particularly useful in managing bleeding in patients with HHT.

otorhinolaryngology
Managing recurrent nosebleeds in children: a retrospective review of 718 children attending a nurse-led epistaxis clinic

Ivy Drake,Hazel Fountain,Haytham Kubba

DOI: https://doi.org/10.1017/s0022215124000069

2024-01-16

The Journal of Laryngology & Otology

Abstract://static.cambridge.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS0022215124000069/resource/name/firstPage-pdf-S0022215124000069a.jpg

otorhinolaryngology
A case report of acute myocardial infarction with hereditary hemorrhagic telangiectasia

Wenping Xue,Wei Qin,Tingting Liu,Weichao Shan

DOI: https://doi.org/10.1186/s13019-024-03106-x

2024-10-17

Journal of Cardiothoracic Surgery

Abstract:Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder characterized by epistaxis, gastrointestinal bleeding, iron deficiency anemia, and arteriovenous malformations (AVMs) affecting the lungs, liver, and brain. Owing to its rarity and diagnostic challenges, early identification is often elusive. Underdiagnosis and prolonged diagnostic delays are prevalent. Here, we present the case of a 63-year-old male who presented with chest pain and was diagnosed with an ST-elevation myocardial infarction (STEMI). Subsequently, he underwent placement of a drug-eluting stent in the right coronary artery (RCA). However, recurrent postoperative epistaxis resulted in severe anemia, prompting further investigation leading to the diagnosis of hereditary hemorrhagic telangiectasia through comprehensive medical history and genetic testing. Future studies are warranted to evaluate reperfusion strategies in HHT patients presenting with myocardial infarction.

surgery,cardiac & cardiovascular systems
Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis

Huimin Chen,Zhiping Zhang,Xiaojuan Chen,Chaoyu Wang,Mingdi Chen,Huizhao Liao,Jinru Zhu,Zhenzhen Zheng,Riken Chen

DOI: https://doi.org/10.3389/fphar.2023.1089847

IF: 5.6

2023-12-13

Frontiers in Pharmacology

Abstract:Objective: A meta-analysis is conducted to evaluate the effectiveness and safety of bevacizumab in hereditary hemorrhagic telangiectasia (HHT) epistaxis. Method: Two researchers search PubMed, EMBASE and Web of Science databases from their inception until September 3th, 2023. The literature is read and screened, and valid data extracted, collated and analyzed. Its quality is then assessed using the Cochrane risk assessment scale. This study uses Endnote 9.3 software for literature management and RevMan 5.3.1 software for evaluation. Results: A total of 7 documents met the requirements, including a total of 359 patients, and the literature quality evaluation was grade B. The Meta-analysis results showed that:Bevacizumab reduces the Epistaxis Severity Score (ESS) in patients with HHT epistaxis compared with the control [WMD = −0.22,95%CI (−0.38, −0.05), p = 0.01]. However, there is no significant effect on duration of epistaxis [WMD = −15.59, 95%CI (−70.41,39.23), p = 0.58] and number of epistaxes [WMD = −1.27,95%CI (−10.23,7.70), p = 0.78] in patients with HHT epistaxis. In terms of adverse effects, there is no significant difference between the bevacizumab group and control group [OR = 1.36, 95% CI (0.54, 3.44), p = 0.52]. Conclusion: Bevacizumab is superior to the control group in the treatment of HHT epistaxis, and adverse reactions are not further increased in the bevacizumab group than in the control group, suggesting that bevacizumab has clinical value in the treatment of HHT epistaxis.

pharmacology & pharmacy

Managing Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT): A Comprehensive Narrative Review of Therapeutic Horizons

Surgical Extraction in a Patient with Hereditary Hemorrhagic Telangiectasia - A Case Report

How I Treat Bleeding in Hereditary Hemorrhagic Telangiectasia

Surgery or No Surgery? Exploring the Dilemma of Epistaxis Management in Patients with HHT

Is there still a role for nasal closure in hereditary haemorrhagic telangiectasia?

Medical and Interventional Management of Hereditary Hemorrhagic Telangiectasia

Hereditary hemorrhagic telangiectasia – pediatric review

Hereditary Hemorrhagic Telangiectasia: A Pediatric-Focused Review

Hereditary hemorrhagic telangiectasia: from signaling insights to therapeutic advances

Hereditary haemorrhagic telangiectasia: A primer for the paediatrician

Pulmonary hypertension in hereditary hemorrhagic telangiectasia: A clinical review

Bevacizumab: an option for refractory epistaxis in hereditary haemorrhagic telangiectasia

S3661 The Perpetual Hemorrhage: Managing Recurrent Gastrointestinal Bleeding in Hereditary Hemorrhagic Telangiectasia

Classification of endonasal HHT lesions using digital microscopy

Second International Guidelines for the Diagnosis and Management of Hereditary Hemorrhagic Telangiectasia

Executive summary of the 14th HHT international scientific conference

Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia

Usefulness of endoscopic endonasal underwater surgery using a combination of coblation and a lens-cleaning system for hemostasis in hereditary hemorrhagic telangiectasia

Managing recurrent nosebleeds in children: a retrospective review of 718 children attending a nurse-led epistaxis clinic

A case report of acute myocardial infarction with hereditary hemorrhagic telangiectasia

Meta-analysis of efficacy and safety of bevacizumab in the treatment of hereditary hemorrhagic telangiectasia epistaxis